Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
AssigneeCuremark, LLC
InventorsJoan M. Fallon, Matthew Heil, James J. FALLON, Janice HUGHES
Life of this patent
Estimating the term…
Abstract
Methods for prophylaxis, treatment, and reduction of infection, re-infection, and transmission rates of Coronaviruses and more particularly Coronavirus Disease 2019 (COVID-19) resulting from a SARS-CoV-2 viral infection with the use of a pharmaceutical preparation comprising one or more coated or uncoated digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes are described herein.
Claims72
A method for treatment, prophylaxis, mitigation, or accelerated recovery of a coronavirus infection in a subject, comprising administering to the subject a pharmaceutical composition that comprises digestive enzymes.
A method of treating a gastrointestinal symptom associated with a Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) infection in a subject in need thereof, comprising administering to the subject a pharmaceutical composition that comprises digestive enzymes;
- wherein the digestive enzymes comprise a protease, a lipase, and an amylase, and wherein the digestive enzymes are provided as pancreatin.
A method for reducing an infection rate of a Severe Acute Respiratory Syndrome (SARS-CoV-2) infection in a subject in need thereof, comprising administering to the subject a pharmaceutical composition that comprises digestive enzymes, wherein the digestive enzymes comprise a protease, an amylase, and a lipase, and wherein the digestive enzymes are provided as pancreatin, and wherein the infection rate is reduced.
A method for reducing a transmission rate of a Severe Acute Respiratory Syndrome (SARS-CoV-2) infection in a subject in need thereof, comprising administering to the subject a pharmaceutical composition that comprises digestive enzymes, wherein the digestive enzymes comprise a protease, an amylase, and a lipase, and wherein the digestive enzymes are provided as pancreatin, and wherein the transmission rate is reduced.
A method of treating long COVID in a subject in need thereof, comprising administering to the subject a pharmaceutical composition that comprises digestive enzymes, wherein the digestive enzymes comprise a protease, an amylase, and a lipase, and wherein the digestive enzymes are provided as pancreatin, and wherein long COVID is treated.
A method of enhancing cytoprotection against a Severe Acute Respiratory Syndrome (SARS-CoV-2) infection in a subject in need thereof, comprising administering to the subject a pharmaceutical composition that comprises digestive enzymes, wherein the digestive enzymes comprise a protease, an amylase, and a lipase, and wherein the digestive enzymes are provided as pancreatin, and wherein cytoprotection is enhanced.
A method of reducing a virus titer of a Severe Acute Respiratory Syndrome (SARS-CoV-2) in a subject in need thereof, comprising administering to the subject a pharmaceutical composition that comprises digestive enzymes, wherein the digestive enzymes comprise a protease, an amylase, and a lipase, and wherein the digestive enzymes are provided as pancreatin, and wherein the virus titer is reduced.
Dependencies are inferred from the claim text.